UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
🤖 D.R.A.F.T. Summary
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44 Duvakitug was well tolerated and safety was consistent with the induction study PARSIPPANY, N.J. and PARIS, Oct.
Outlets covering this story
Financial Post
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →